Printer Friendly

ZYNAXIS REPORTS FIRST QUARTER RESULTS

 ZYNAXIS REPORTS FIRST QUARTER RESULTS
 MALVERN, Pa., May 15 /PRNewswire/ -- Zynaxis, Inc. (NASDAQ: ZNXS)


today reported a net loss of $0.20 per share for the quarter ended March 31, 1992. This compares with a net loss of $0.38 per share for first quarter a year ago.
 Commenting on the results, Thomas Cekoric Jr., Zynaxis' president, stated, "Contributing to our loss for the quarter was a 15 percent increase in research and development costs, as we continue to further develop our proprietary Zyn-Linker technology. We are in a very strong cash position and have adequate resources to continue our research for commercialization of our technology."
 Zynaxis, Inc. is a biotechnology company engaged in the development of new therapeutic delivery systems and an advanced cellular diagnostic system. The company has $22 million in cash at the time of this report.
 ZYNAXIS, INC.
 (In thousands, except per-share data)
 Period ended March 31 1991 1992
 Revenues -- --
 Research and development $ 581 $ 671
 General & administrative 123 225
 Total operating expenses 704 896
 Interest income (net) (3) 106
 Net loss $ (707) $ (790)
 Net loss per share $ (0.38) $ (0.20)
 Weighted average shares outstanding 1,875,632 3,866,806
 -0- 5/15/92
 /CONTACT: Thomas Cekoric Jr., president of Zynaxis, 215-889-2200, or Susan Sherman of Cameron Associates, 212-644-9560, for Zynaxis/
 (ZNXS) CO: Zynaxis, Inc. ST: Pennsylvania IN: MTC SU: ERN


TQ-OS -- NY081 -- 0859 05/15/92 15:18 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:May 15, 1992
Words:235
Previous Article:SALVATORI OPHTHALMICS, INC. ANNOUNCES PROPOSED ACQUISITION OF G.T. LABORATORIES, INC. AND FUSED KONTACTS, INC.
Next Article:AGENCY FOR HEALTH CARE POLICY AND RESEARCH TO SPONSOR WORKSHOP
Topics:


Related Articles
ZYNAXIS, INC. FILES FOR PROPOSED PUBLIC OFFERING
ZYNAXIS AND ELI LILLY ENTER INTO A COLLABORATIVE PROGRAM TO DEVELOP DRUG DELIVERY PRODUCTS FOR CARDIOVASCULAR DISEASE
ZYNAXIS REPORTS SECOND QUARTER AND SIX MONTH RESULTS
WALTER BRANDES JOINS ZYNAXIS AS VICE PRESIDENT OF SALES AND MARKETING
ZYNAXIS REPORTS THIRD QUARTER AND NINE MONTH RESULTS
ZYNAXIS REPORTS FOURTH QUARTER AND YEAR END RESULTS
MARTYN GREENACRE ASSUMES CHAIRMAN OF THE BOARD POSITION OF ZYNAXIS
ZYNAXIS(R) REPORTS FIRST QUARTER RESULTS
ZYNAXIS REPORTS THIRD QUARTER 1994 FINANCIAL RESULTS
ZYNAXIS REPORTS 1994 FOURTH QUARTER AND YEAR-END RESULTS

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters